XML 173 R8.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Consolidated net loss $ (63,746) $ (177,536)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Depreciation and amortization 12,803 12,739
Non-cash operating lease cost 1,461 2,155
Stock-based compensation to employees and directors 8,002 16,384
Gain on sale of intangible assets (5,790) (10,250)
Write-down of assets held for sale 0 1,648
Loss from equity method securities 16,644 43,405
Other non-cash adjustments 1,720 (216)
Changes in operating assets and liabilities:    
Accounts receivable, net (1,460) 4,393
Inventories 4,333 1,982
Prepaids and other current assets 2,251 (438)
Other long-term assets, net (493) (1,335)
Accounts payable 12,375 (18,554)
Accrued liabilities (26,990) (19,372)
Unearned revenue (7,275) (4,648)
Operating lease liabilities (1,016) (2,168)
Other long-term liabilities (3,031) (814)
Net cash used in operating activities (50,212) (152,625)
Cash flows from investing activities:    
Purchase of equity securities (8,000) 0
Disbursement for notes receivable (8,232) 0
Purchase of intangible assets (15,214) (6,033)
Expenditures for property and equipment (5,249) (11,329)
Proceeds from the sale of intangible assets 6,250 10,250
Other investing activities, net 29 566
Net cash used in investing activities (30,416) (6,546)
Cash flows from financing activities:    
Proceeds from sale of common stock, net of offering costs 101,690 0
Payments on short-term debt (7,000) 0
Repurchase of shares (6,218) 0
Payments of taxes withheld upon vesting of employee stock awards (544) (3,271)
Other financing activities, net 1,024 1,190
Net cash provided by (used in) financing activities 88,952 (2,081)
Net (decrease) increase in cash, cash equivalents, and restricted cash 8,324 (161,252)
Cash, cash equivalents, and restricted cash, beginning of period 186,093 302,749
Cash, cash equivalents, and restricted cash, end of period $ 194,417 $ 141,497